News
Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.
The FDA has denied that it plans to combine the Center for Drug Evaluation and Research and Center for Biologics Evaluation ...
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Vinay Prasad’s ouster as the Food and Drug Administration’s top vaccine and gene therapy regulator came after frustration ...
A biopharmaceutical research company with ties in Andover has laid off a third of its workforce as one of the industry leaders in gene therapy goes through a “strategic restructuring.” Sarepta ...
PTC Therapeutics faces pivotal FDA decisions for approvals that could potentially transform their long-term revenues. Click ...
21h
Pharmaceutical Technology on MSNGeorge Tidmarsh to sub in as FDA CBER head following Prasad’s shock exit
Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.
From the meme stock revival to Trump's Fed feud, Peter Hodson looks at some of the summer's more bizarre trends ...
Donald Trump reportedly ignored calls from Health Secretary Robert F. Kennedy Jr. not to fire the top vaccine official at the Food and Drug Administration after a pressure campaign from far-right ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results